AAV is a promising delivery vehicle for gene therapies with potential to be engineered for improved targeting, higher potency and lower immunogenicity. However, challenges also remain to improve their manufacturing and stability to achieve lower costs and ease of formulation and delivery.  Protein engineering provides a viable route to creating platform vectors ready-made for low cost…